Biostax Launches Growth Round with Deal Box’s capital raise technology to fund the development of programs that treat autoimmune and inflammatory diseases.

Company will levera Deal Box's capital raising technology and Investment Packaging (™) formula to raise up to $5 million

HUB-AND-SPOKE BIOTECH DEVELOPMENT ENGINE POWERING EFFICEINT SMALL-SCALE MED-TECH, PHARMACEUTICAL AND BIOTECHNOLOGY PROGRAMS

Paradigm shifting development of health tech and the treatment of autoimmunity, chronic inflammation, infection, and cancer

This website may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions, and expectations of Biostax’s future economic performance, considering the information currently available to it. These statements are not statements of historical fact. Although Biostax believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Biostax does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Biostax will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks, and uncertainties, some of which are not currently known to us, that may cause Biostax’s actual results, performance, or financial condition to be materially different from the expectations of future results, performance, or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory review and approval of our prospective products, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

The information provided in this website is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Section 1

Biostax Launches Growth Round with Deal Box’s capital raise technology to fund the development of programs that treat autoimmune and inflammatory diseases.

Company will levera Deal Box's capital raising technology and Investment Packaging (™) formula to raise up to $5 million

Section 1

HUB-AND-SPOKE BIOTECH DEVELOPMENT ENGINE POWERING EFFICEINT SMALL-SCALE MED-TECH, PHARMACEUTICAL AND BIOTECHNOLOGY PROGRAMS

Paradigm shifting development of health tech and the treatment of autoimmunity, chronic inflammation, infection, and cancer